Eliaz Therapeutics Launches Reg CF Raise to Advance First Device Targeting Sepsis

Eliaz Therapeutics announced that its XGal-3 apheresis device has received FDA Breakthrough Device Designation for treating sepsis, a leading cause of death in ICUs. The company is launching a Regulation Crowdfunding round to support GLP safety studies and first-in-human clinical trials. With $8M raised to date from over 1,700 investors and support from NIH grants and Terumo BCT collaboration, XGal-3 aims to selectively remove Galectin-3 protein to address inflammatory dysregulation in sepsis.